actin-binding fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-21. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
=== Osteoclasts === Osteoclasts are multinucleated cells that derive from hematopoietic progenitors in the bone marrow which also give rise to monocytes in peripheral blood. Osteoclasts break down bone tissue, and along with osteoblasts and osteocytes form the structural components of bone. In the hollow within bones are many other cell types of the bone marrow. Components that are essential for osteoblast bone formation include mesenchymal stem cells (osteoblast precursor) and blood vessels that supply oxygen and nutrients for bone formation. Bone is a highly vascular tissue, and active formation of blood vessel cells, also from mesenchymal stem cells, is essential to support the metabolic activity of bone. The balance of bone formation and bone resorption tends to be negative with age, particularly in post-menopausal women, often leading to a loss of bone serious enough to cause fractures, which is called osteoporosis.
=== Film performances === Culp worked as an actor in many theatrical films, beginning with three in 1963: As naval officer John F. Kennedy's good friend Ensign George Ross in PT 109, as legendary gunslinger Wild Bill Hickok in The Raiders, and as the debonair fiancé of Jane Fonda in Sunday in New York. He starred in Bob & Carol & Ted & Alice in 1969, with Natalie Wood. Another memorable role came as another gunslinger, Thomas Luther Price, in Hannie Caulder (1971) opposite Raquel Welch. A year later, Hickey & Boggs reunited him with Cosby for the first time since I Spy. Culp also directed this feature film, in which Cosby and he portray over-the-hill private eyes. In 1986, he had a primary role as General Woods in the comedy Combat Academy. Culp played the U.S. President in Alan J. Pakula's 1993 murder mystery, The Pelican Brief.
His left ankle wounded, he surrendered to Pallavicini, who transported him to La Spezia, where he was imprisoned in the Varignano fortress. Although he was later amnestied, the affair caused a political earthquake in Italy, culminating in Rattazzi's resignation as head of government and accusations against the King that he had misled Garibaldi about the feasibility of the enterprise, and abandoned him when he became inconvenient. Calabria was the scene of post-unification brigandage, which was endemic in the Mezzogiorno. It also connoted legitimist aspirations during the transition between Bourbon and Italian rule. Bourbon legitimists and the government of Francis II of the Two Sicilies (in exile in Rome) attempted to guide the bands of brigands in the south, who attacked exponents of the liberal regime (the “galantuomini”). They were typically supporters of the agrarian bourgeoisie. José Borjes led the Borjes Expedition, a Bourbon legitimist attempt to reconquer the Kingdom of Naples. Borjes was a Catalan general distinguished in the Carlist wars in Spain. He attempted to imitate Cardinal Fabrizio Ruffo's Sanfedist expedition sixty years earlier. After receiving reassurance that the local population would support his cause, Borjes departed from Malta and landed in Brancaleone on 14 September 1861 with 21 men. Borjes' goal was to make contact with the brigands and unite them to reconquer Neapolitan territory. To this end, he joined the band of Ferdinando Mittiga, a brigand chief operating in the area in command of 120 men.
Juniper is an online weight-management company operated by Eucalyptus Health. It provides telehealth-based care. Its core offerings include weight management and menopause-related services. The service operates in Australia, the United Kingdom, Germany, Japan and Canada. Juniper's programs are accessed through an online intake and clinician-led consultation. The program is combined with lifestyle support (referred to as health coaching), and may include prescription treatment with glucagon-like peptide-1 (GLP-1) receptor agonist medications, such as semaglutide (sold as Wegovy or Ozempic) and tirzepatide (Mounjaro), where clinically appropriate and allowed by local laws.
=== Source and biosynthesis === Valine, like other branched-chain amino acids, is synthesized by bacteria and plants, but not by animals. It is therefore an essential amino acid in animals, and needs to be present in the diet. Adult humans require about 24 mg/kg body weight daily. It is synthesized in plants and bacteria via several steps starting from pyruvic acid. The initial part of the pathway also leads to leucine. The intermediate α-ketoisovalerate undergoes reductive amination with glutamate. Enzymes involved in this biosynthesis include:
Sources: en.wikipedia.org
=== Sahrawi Arab Democratic Republic === The Castillo Administration recognized the Sahrawi Arab Democratic Republic, a partially-recognized state claimed by Morocco. Although the recognition came without forewarning, officially it was due to Castillo's push for a foreign policy based on self-determination and non-intervention. The Congressional opposition has opposed the recognition of the SADR, claiming that it creates geopolitical instability and risks Peru's relations with the Middle East.
== Recognition == 1989 – Award of the Mass Spectrometry Society of Japan 2002 – Nobel Prize in Chemistry 2002 – Order of Culture 2002 – Person of Cultural Merit 2002 – Honorary doctorate from Tohoku University 2003 – Honorary citizenship of Toyama Prefecture 2003 – Special Award of the Mass Spectrometry Society of Japan 2006 – Member of Japan Academy 2024 – IEEE Milestone for "LAMS-50K" (one of the 5-member development team)
Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication. It was approved for medical use in the European Union in October 2005, and in the United States in September 2006. It is available as a generic medication.
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1).
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.